Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of rhIL-7-hyFc, a Hybrid Fc-Fused Long-Acting Interleukin-7, to Support Optimal Dosing Regimens in Patients with Solid Cancer.
Saved in:
| Title: | Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of rhIL-7-hyFc, a Hybrid Fc-Fused Long-Acting Interleukin-7, to Support Optimal Dosing Regimens in Patients with Solid Cancer. |
|---|---|
| Authors: | Park S; Department of Clinical Pharmacology and Therapeutics, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Lee SM; Department of Clinical Pharmacology and Therapeutics, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Pak KC; Department of Clinical Pharmacology and Therapeutics, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea., Byun MS; Genexine, Inc., Seoul, Republic of Korea., Choi D; Neoimmunetech, Inc., Rockville, MD, USA., Lim HS; Department of Clinical Pharmacology and Therapeutics, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. |
| Source: | Drug design, development and therapy [Drug Des Devel Ther] 2025 Oct 17; Vol. 19, pp. 9303-9320. Date of Electronic Publication: 2025 Oct 17 (Print Publication: 2025). |
| Publication Type: | Journal Article; Clinical Trial, Phase I |
| Journal Info: | Publisher: Dove Press Limited Country of Publication: New Zealand NLM ID: 101475745 Publication Model: eCollection Cited Medium: Internet ISSN: 1177-8881 (Electronic) Linking ISSN: 11778881 NLM ISO Abbreviation: Drug Des Devel Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41127361 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of rhIL-7-hyFc, a Hybrid Fc-Fused Long-Acting Interleukin-7, to Support Optimal Dosing Regimens in Patients with Solid Cancer. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Park+S%22">Park S</searchLink>; Department of Clinical Pharmacology and Therapeutics, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Lee+SM%22">Lee SM</searchLink>; Department of Clinical Pharmacology and Therapeutics, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Pak+KC%22">Pak KC</searchLink>; Department of Clinical Pharmacology and Therapeutics, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Byun+MS%22">Byun MS</searchLink>; Genexine, Inc., Seoul, Republic of Korea.<br /><searchLink fieldCode="AU" term="%22Choi+D%22">Choi D</searchLink>; Neoimmunetech, Inc., Rockville, MD, USA.<br /><searchLink fieldCode="AU" term="%22Lim+HS%22">Lim HS</searchLink>; Department of Clinical Pharmacology and Therapeutics, Asan Medical Institute of Convergence Science and Technology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101475745%22">Drug design, development and therapy</searchLink> [Drug Des Devel Ther] 2025 Oct 17; Vol. 19, pp. 9303-9320. <i>Date of Electronic Publication: </i>2025 Oct 17 (<i>Print Publication: </i>2025). – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase I – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Dove+Press+Limited%22">Dove Press Limited </searchLink><i>Country of Publication: </i>New Zealand <i>NLM ID: </i>101475745 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1177-8881 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2211778881%22">11778881 </searchLink><i>NLM ISO Abbreviation: </i>Drug Des Devel Ther <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41127361 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.2147/DDDT.S564085 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 9303 Titles: – TitleFull: Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of rhIL-7-hyFc, a Hybrid Fc-Fused Long-Acting Interleukin-7, to Support Optimal Dosing Regimens in Patients with Solid Cancer. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Park S – PersonEntity: Name: NameFull: Lee SM – PersonEntity: Name: NameFull: Pak KC – PersonEntity: Name: NameFull: Byun MS – PersonEntity: Name: NameFull: Choi D – PersonEntity: Name: NameFull: Lim HS IsPartOfRelationships: – BibEntity: Dates: – D: 17 M: 10 Text: 2025 Oct 17 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1177-8881 Numbering: – Type: volume Value: 19 Titles: – TitleFull: Drug design, development and therapy Type: main |
| ResultId | 1 |
